Fujimoto S, Miyazaki M, Endoh F, Takahashi O, Shrestha R D, Okui K, Morimoto Y, Terao K
Cancer. 1985 Feb 1;55(3):522-6. doi: 10.1002/1097-0142(19850201)55:3<522::aid-cncr2820550309>3.0.co;2-s.
We prepared biodegradable microspheres containing about 5% mitomycin C (MMC) and of 45 +/- 8 microns in diameter. These preparations were infused into the rat hepatic artery as a preclinical model of intra-arterial infusion treatment for patients with inoperable hepatic tumor. The leaked MMC levels in the hepatic vein decreased below the assay limitation 2 hours after conventional MMC injection, whereas in the case of MMC microsphere the leaked drug levels were maintained at almost the same concentration for over 2 hours after infusion. The entrapped period of MMC microspheres within the hepatic artery was at least 2 weeks, and the necrobiotic foci due to antitumor effects of the condensed MMC released from the microspheres were observed in the area fed by these entrapped arterioles. This phenomenon was never observed in the case of conventional MMC and placebo microspheres. Intra-arterial infusion of MMC microspheres may be a promising clinical treatment for patients with malignant hepatic tumor.
我们制备了含有约5%丝裂霉素C(MMC)且直径为45±8微米的可生物降解微球。将这些制剂注入大鼠肝动脉,作为无法手术的肝肿瘤患者动脉内灌注治疗的临床前模型。常规MMC注射后2小时,肝静脉中泄漏的MMC水平降至检测限以下,而在MMC微球的情况下,输注后2小时以上泄漏药物水平几乎维持在相同浓度。MMC微球在肝动脉内的滞留期至少为2周,在由这些滞留小动脉供血的区域观察到了因微球释放的浓缩MMC的抗肿瘤作用而产生的坏死灶。在常规MMC和安慰剂微球的情况下从未观察到这种现象。MMC微球的动脉内灌注可能是恶性肝肿瘤患者一种有前景的临床治疗方法。